We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current FATE market cap is 136.41M. The company's latest EPS is USD -1.6249 and P/E is -0.70.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.93M | 6.77M | 3.07M | 1.86M | 1.63M |
| Operating Income | -51.07M | -45.08M | -52.38M | -61.75M | -41.28M |
| Net Income | -48M | -38.43M | -47.68M | -52.15M | -37.62M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 31.43M | 55.85M | 96.3M | 63.53M | 13.63M |
| Operating Income | -128.09M | -216.99M | -308.39M | -190.51M | -210.28M |
| Net Income | -173.39M | -212.15M | -281.72M | -160.93M | -186.26M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 569.89M | 528.82M | 494.97M | 440.69M | 398.67M |
| Total Liabilities | 143.78M | 131.84M | 132.64M | 121.97M | 110.26M |
| Total Equity | 426.12M | 396.98M | 362.33M | 318.73M | 288.41M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 622.46M | 921.46M | 705.56M | 506.22M | 440.69M |
| Total Liabilities | 238.01M | 242.62M | 221.62M | 137.8M | 121.97M |
| Total Equity | 384.45M | 678.84M | 483.94M | 368.42M | 318.73M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -33.35M | -65.66M | -95.08M | -122.87M | -33.81M |
| Investing | 17.31M | -36.06M | -10.6M | 12.22M | 42.67M |
| Financing | 95.49M | 96.76M | 96.76M | 99.89M | N/A |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -39.23M | -162.87M | -248.21M | -132.26M | -122.87M |
| Investing | -161.08M | -324.02M | 166.75M | 112.67M | 12.22M |
| Financing | 282.84M | 453.13M | 9.21M | 85k | 99.89M |
| Market Cap | 136.41M |
| Price to Earnings Ratio | -0.70 |
| Price to Sales Ratio | 9.5 |
| Price to Cash Ratio | 3.59 |
| Price to Book Ratio | 0.41 |
| Dividend Yield | - |
| Shares Outstanding | 114.63M |
| Average Volume (1 week) | 1.04M |
| Average Volume (1 Month) | 1.53M |
| 52 Week Change | -73.14% |
| 52 Week High | 5.92 |
| 52 Week Low | 0.66105 |
| Spread (Intraday) | 0.42 (28.38%) |
| Company Name | Fate Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.fatetherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
